Abstract
Various types of nanoparticles, such as liposomes, polymeric micelles, dendrimers, superparamagnetic iron oxide crystals, and colloidal gold, have been employed in targeted therapies for cancer. Both passive and active targeting strategies can be utilized for nanodrug delivery. Passive targeting is based on the enhanced permeability and retention (EPR) effect of the vasculature surrounding tumors. Active targeting relies on ligand-directed binding of nanoparticles to receptors expressed by tumor cells. Release of loaded drugs from nanoparticles may be controlled in response to changes in environmental condition such as temperature and pH. Biodistribution profiles and anticancer efficacy of nano-drugs in vivo would be different depending upon their size, surface charge, PEGylation and other biophysical properties. This review focuses on the recent development of nanoparticles for tumor targeted therapies, including physicochemical properties, tumor targeting, control of drug release, pharmacokinetics, anticancer efficacy and safety. Future perspectives are discussed as well.
Keywords: Nanoparticles, tumor targeting, release, pharmacokinetics, safety
Current Drug Metabolism
Title: Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Volume: 11 Issue: 2
Author(s): Jianqiu Wang, Meihua Sui and Weimin Fan
Affiliation:
Keywords: Nanoparticles, tumor targeting, release, pharmacokinetics, safety
Abstract: Various types of nanoparticles, such as liposomes, polymeric micelles, dendrimers, superparamagnetic iron oxide crystals, and colloidal gold, have been employed in targeted therapies for cancer. Both passive and active targeting strategies can be utilized for nanodrug delivery. Passive targeting is based on the enhanced permeability and retention (EPR) effect of the vasculature surrounding tumors. Active targeting relies on ligand-directed binding of nanoparticles to receptors expressed by tumor cells. Release of loaded drugs from nanoparticles may be controlled in response to changes in environmental condition such as temperature and pH. Biodistribution profiles and anticancer efficacy of nano-drugs in vivo would be different depending upon their size, surface charge, PEGylation and other biophysical properties. This review focuses on the recent development of nanoparticles for tumor targeted therapies, including physicochemical properties, tumor targeting, control of drug release, pharmacokinetics, anticancer efficacy and safety. Future perspectives are discussed as well.
Export Options
About this article
Cite this article as:
Wang Jianqiu, Sui Meihua and Fan Weimin, Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics, Current Drug Metabolism 2010; 11 (2) . https://dx.doi.org/10.2174/138920010791110827
DOI https://dx.doi.org/10.2174/138920010791110827 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Tyrosine Phosphatase Inhibitors in Cancer Treatment with Emphasis on SH2 Domain-Containing Tyrosine Phosphatases (SHPs)
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology Editorial (Hot Topics: Naturally Occurring Molecules and Anticancer Combination Therapies in the Era of Personalized Medicine and Economic Crisis)
Current Pharmaceutical Design Targeting EZH2 for Cancer Therapy: Progress and Perspective
Current Protein & Peptide Science New Purine Nucleoside Analogs for Acute Lymphoblastic Leukemia
Clinical Cancer Drugs Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Current Pharmaceutical Design Impact of Immunogenetic Polymorphisms in Bone Marrow Failure Syndromes
Mini-Reviews in Medicinal Chemistry Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Current Medicinal Chemistry Low Dose of Anisodine Hydrobromide Induced Neuroprotective Effects in Chronic Cerebral Hypoperfusion Rats
CNS & Neurological Disorders - Drug Targets Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Editorial [Hot Topic: Novel and Emerging Drugs for Leukemias (Guest Editor: Tadeusz Robak)]
Current Cancer Drug Targets The Family is Growing: Old and New Members of the Family of Site- Specific Recombinases and Their Application to Genome Engineering
Current Pharmacogenomics Structure-activity Relationship Studies of New Marine Anticancer Agents and their Synthetic Analogues
Current Medicinal Chemistry Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews Prodrugs of Non-steroidal Anti-inflammatory Drugs (NSAIDs): A Long March Towards Synthesis of Safer NSAIDs
Mini-Reviews in Medicinal Chemistry Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design